You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK):附屬研發胰島素注射液整體安全性良好
阿思達克 07-30 12:23
四環醫藥(00460.HK)公布,旗下非全資附屬(間接持股約82.68%)吉林惠升生物製藥研發的門冬胰島素30注射液在與二甲雙胍聯合治療口服降糖藥控制不佳的2型糖尿病的有效性與安全性研究中,與陽性對照藥相比臨床療效相當,整體安全性良好。

該研究結果顯示,中國口服降糖藥控制不佳的2型糖尿病患者每日兩次早、晚餐前皮下注射吉林惠升生物製藥生產的門冬胰島素30注射液,主要療效指標糖化血蛋白的降低非劣於諾和諾德公司生產的諾和銳30,其他次要療效指標兩組間差異均無統計學差異,同時安全性良好。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account